[Hydronephrosis as a prognostic factor for patients of figo IIIB cervical cancer].
OBJECTIVE
The aim of this study was to assess whether hydronephrosis is a prognostic factor for patients of FIGO stage III B cervical cancer.


METHODS
A retrospective review of 145 stage III B cervical cancer patients treated with radiotherapy between 1989-1993 at Maria Skłodowska-Curie Memorial Cancer Center in Warsaw was performed. Radiotherapy consisted of External Beam Irradiation (EBI) and Brachytherapy (BT) or EBI alone.


RESULTS
Multivariate analysis revealed that hydronephrosis and Brachytherapy following EBI as the second part of the treatment were statistically significant factors in survival of FIGO stage III B cervical cancer patients. The five-year survival rate was 36% for patients without hydronephrosis treated with EBI and BT, compared to the group with hydronephrosis treated with EBI alone (no regression or too slow regression of the tumor to use BT), in which the survival rate was only 17 months.


CONCLUSIONS
FIGO III b cervical cancer patients with hydronephrosis are treated only with palliative intent.
Krynicki
Ryszard
R
Kliniki Nowotworów Narzadów Płciowych Kobiecych Centrum Onkologii-Instytut w Warszawie.
Bidziński
Mariusz
M
Wierzba
Waldemar
W
Panek
Grzegorz
G
Jońska
Joanna
J
Lindner
Bogusław
B
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods; D018572:Disease-Free Survival; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology*; D008875:Middle Aged; D009367:Neoplasm Staging; D011044:Poland; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000532:radiotherapy*
Zastój moczu jako czynnik prognostyczny u chorych na raka szyjki macicy w IIIB stopniu klinicznego zaawansowania.